Scleroderma is a connective tissue disease characterized by inflammation, degeneration, thickening and fibrosis of the skin leading to sclerosis and atrophy, which can cause multisystemic damage. Systemic sclerosis is characterized by degenerative lesions of the skin, synovium, and finger (toe) arteries, as well as involvement of internal organs such as the digestive tract, lungs, heart, and kidneys. Systemic sclerosis is a chronic multi-system disease. Initial symptoms are often nonspecific and include Raynaud’s phenomenon, malaise, and musculoskeletal pain, which persist for weeks or months before other indications appear. The early clinical manifestation of scleroderma with specificity is a swelling and thickening of the skin, beginning in the fingers and hands. A wide variety of manifestations follow, mainly in the skin, lungs, heart, digestive tract, or kidneys. There is an increased risk of kidney involvement in patients without Raynaud’s phenomenon. Depending on the degree of skin involvement, scleroderma can be divided into several subtypes: (1) limited scleroderma, in which the skin of the distal limbs is thickened only, and the trunk is not affected; the CREST syndrome, which includes calcium deposits, Raynaud’s phenomenon, esophageal dysfunction, sclerosis of the digits, and capillary dilatation, is categorized as a limited scleroderma; (2) diffuse scleroderma, in which the skin of the fingers and hands is thickened only. Patients with diffuse scleroderma exhibit skin thickening of the distal and proximal extremities and/or trunk.